额颞叶痴呆体液标志物研究进展  

Advances in Fluid Biomarkers of Frontotemporal Dementia

作　　者：王玥 刘益萌[1,2] WANG Yue;LIU Yimeng(The National Clinical Research Center for Mental Disorders&Beijing Key Laboratory of Mental Disorders,Beijing Anding Hospital,Capital Medical University,Beijing 100088,China;Advanced Innovation Center for Human Brain Protection,Capital Medical University,Beijing 100069,China)

机构地区：[1]首都医科大学附属北京安定医院/国家精神心理疾病临床医学研究中心/精神疾病诊断与治疗北京市重点实验室,北京100088 [2]首都医科大学人脑保护高精尖创新中心,北京100069

出　　处：《神经损伤与功能重建》2024年第12期784-787,802,共5页Neural Injury and Functional Reconstruction

基　　金：北京市自然科学基金面上项目(疾病相关小胶质细胞亚型在1型糖尿病认知功能障碍中的作用及机制研究,No.7222064)。

摘　　要：额颞叶痴呆(frontotemporal dementia,FTD)是常见的神经变性病和早发型痴呆,突出表现为精神行为异常和认知障碍,由于发病机制不清、异质性突出,目前早期诊断和治疗困难。近年来由于技术不断成熟,FTD体液标志物相关研究成为热点,有较多研究已经发现了一些有潜在应用价值的标志物分子。本文特将近期相关研究归纳总结,以期临床医生能够了解FTD早期诊断标志物的研究进展,为后续的基础研究提供参考方向,为临床应用提供可能选择。Frontotemporal dementia(FTD)is a common neurodegenerative disorder and an early-onset form of dementia,characterized by prominent psychiatric and behavioral abnormalities and cognitive impairment.Due to its unclear pathogenesis and marked heterogeneity,early diagnosis and treatment are currently challenging.In recent years,as technology has matured,research on FTD biofluid markers has become a hot topic,with many studies identifying potential marker molecules for application.This article summarizes recent related research in order to provide clinicians with an understanding of the progress in early diagnostic markers for FTD,to offer reference directions for subsequent basic research,and to present possible options for clinical application.

关 键 词：额颞叶痴呆 体液标志物 早期诊断 综述 

分 类 号：R741[医药卫生—神经病学与精神病学] R741.02[医药卫生—临床医学] R742